Welcome to our dedicated page for HILS news (Ticker: HILS), a resource for investors and traders seeking the latest updates and insights on HILS stock.
Hillstream BioPharma news covers the biotechnology issuer's transition into Tharimmune, including the corporate name and ticker change, clinical-stage licensing activity, and pipeline repositioning from oncology biologics toward inflammatory and immunology-related therapeutic candidates.
Recurring announcements include TH104 and AV104 chronic pruritis development, conference presentations, and historical oncology program updates involving HSB-3215, HER2/HER3 antibodies, Quatramer and Quatrabody technology, Picobodies, Minotaur Therapeutics and OmniAb.
Tharimmune (Nasdaq: THAR), a clinical-stage biotech company, has announced its participation in three major scientific conferences this Fall to present new results about their therapeutic developments. The company will present at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Phoenix (October 24-29, 2025), the American Association for the Study of Liver Diseases (AASLD) Annual Conference in Washington, DC (November 7-10, 2025), and the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 in San Antonio (November 9-12, 2025).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.